Deep Brain Stimulation Efficacy for Treatment-Resistant Depression
Deep brain stimulation (DBS) targeting the subcallosal cingulate (Brodmann area 25) demonstrates long-term response rates of approximately 55-75% at 24 months, with remission rates of 35-50%, though these results come primarily from open-label studies rather than sham-controlled trials.
Evidence Quality and Key Findings
The most recent and comprehensive evidence comes from a 2025 pooled analysis of 172 implanted patients across 5 studies 1. This analysis showed:
- 43% average MADRS reduction at 12 months
- 53% average MADRS reduction at 24 months
- Response rates: 46% at 12 months, 55% at 24 months
- Partial response rates: 13.3% at 12 months, 15.5% at 24 months
These findings represent sustained and continuous improvement from the first year onward, with effectiveness maintained through 5 years of follow-up in available data.
Critical Caveat: The Sham-Control Problem
The most important limitation is that sham-controlled trials have not consistently demonstrated superiority over placebo. A 2024 meta-analysis of 7 randomized controlled trials found that while DBS produces 47% improvement in depression scores long-term, the time course of improvement with active stimulation could not be adequately distinguished from sham stimulation 2. Additionally, a 2025 Canadian RCT (the largest single-center sham-controlled study) found no significant differences between active and sham stimulation groups at 6 months, though the OFF-OFF group numerically outperformed the ON-ON group 3.
Long-Term Outcomes from Open-Label Studies
Multiple independent open-label studies consistently show robust long-term efficacy:
2019 study (n=28,4-8 years follow-up): Response and remission rates maintained at ≥50% and ≥30% respectively through years 2-8, with 21% showing continuous response from year one onward 4
2011 study (3-6 years follow-up): Response rates of 62.5% at 1 year, 46.2% at 2 years, 75% at 3 years, and 64.3% at last follow-up 5
2012 Spanish study (n=8): 62.5% response rate and 50% remission rate at 1 year 6
Patient Selection Considerations
Based on 2022 consensus guidelines, patients receiving DBS typically represent the most severe TRD cases 7:
- Average 8.1 years in current depressive episode 1
- 88% had previously received electroconvulsive therapy 1
- Multiple failed medication trials and augmentation strategies
Important guideline recommendation: Patients in whom DBS or vagus nerve stimulation has previously failed should be excluded from TRD clinical studies (62% consensus), as these individuals represent an even more treatment-refractory population 7.
Safety Profile
The safety data from 151 implanted subjects with 523 patient-years showed 1:
- Suicide incidence: 0.55 per 100 patient-years
- No significant adverse events from acute or chronic stimulation 4
- Surgical complication rates consistent with DBS for other indications 4
- Two suicide deaths occurred during depressive relapses in long-term follow-up 5
Clinical Interpretation
The disconnect between open-label success and sham-controlled failure suggests substantial placebo/expectancy effects. The 2025 Canadian trial specifically noted that future RCTs must account for non-specific procedural effects and employ sufficiently long trial designs 3. The 2024 meta-analysis confirmed that open-label trials showed significantly greater treatment effects than randomized controlled trials 2.
For clinical decision-making: DBS remains experimental for TRD. While long-term open-label data are encouraging, the lack of consistent sham-controlled efficacy means this intervention should only be considered for the most severe, treatment-refractory cases within research protocols that incorporate biomarker-guided programming and optimal white matter tract engagement 3.
The time to reach 50% improvement is estimated at approximately 23 months 2, meaning patients and clinicians must commit to extended treatment periods before determining efficacy.